Sarclisa Escena FDA Approval: Sanofi Transforms Multiple Myeloma Treatment Delivery

Sarclisa Escena Advances Multiple Myeloma Treatment Convenience

Sanofi has reached an important milestone in multiple myeloma treatment with Sarclisa Escena, a subcutaneous version of isatuximab-irfc designed for administration using the CirCLIQ on-body injector. The U.S. Food and Drug Administration granted approval on July 9, 2026, marking the first authorization of an anticancer therapy delivered through an on-body injector. The Sarclisa Escena approval highlights the industry's continued movement toward convenient and patient-focused treatment approaches.

Sarclisa Escena Approval Expands Multiple Myeloma Administration Options

The Sarclisa Escena FDA approval does not introduce a new indication for SARCLISA but provides an alternative administration method for its existing uses. The therapy is approved for newly diagnosed patients who are not eligible for autologous stem cell transplantation when combined with bortezomib, lenalidomide, and dexamethasone. It is also indicated for relapsed or refractory disease alongside pomalidomide and dexamethasone following at least two prior therapies, as well as in combination with carfilzomib and dexamethasone following one to three previous treatment lines.

Sarclisa Escena FDA Approval Supported by Phase III Evidence

The Sarclisa FDA approval 2026 was supported by results from the Phase III IRAKLIA study, which evaluated subcutaneous administration in patients with relapsed or refractory multiple myeloma. When administered with pomalidomide and dexamethasone, the treatment generated an objective response rate of 71.1%, compared with 70.5% for intravenous SARCLISA used with the same combination. These results met the study's predefined non-inferiority criteria. Systemic administration-related reactions were also less frequent with the subcutaneous approach, reported in 1.5% of patients compared with 25% receiving intravenous therapy.

Isatuximab-irfc Brings Wearable Delivery Technology to Oncology

The active ingredient isatuximab-irfc is being paired with innovative wearable technology through CirCLIQ, an on-body injector developed using Enable Injections' enFuse platform. The device is designed to administer treatment automatically while attached to the patient's body. This approach may reduce the time associated with traditional intravenous infusions while potentially decreasing demands on healthcare professionals and infusion centers.

Sanofi Sarclisa Escena Strengthens Multiple Myeloma Innovation

The Sanofi Sarclisa Escena strategy combines an established anti-CD38 monoclonal antibody with an alternative drug-delivery platform. The availability of a wearable administration option provides healthcare professionals and patients with greater flexibility in managing treatment. Sanofi has also obtained subcutaneous approvals for SARCLISA in the European Union and United Kingdom, indicating the company's broader focus on expanding more convenient treatment formats.

Isatuximab FDA Approval Supports Flexible Cancer Care

The isatuximab FDA approval builds upon the established clinical role of SARCLISA in multiple myeloma. Offering the therapy through an automated injector, alongside existing administration approaches, may help address some of the practical challenges associated with repeated infusion-based cancer treatment. The innovation also demonstrates how advances in drug-delivery technology can complement established oncology therapies without requiring changes to the underlying therapeutic mechanism.